Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression

被引：421

作者：

Bangsberg, David R.

机构：

[1] Univ Calif San Francisco, Epidemiol & Prevent Intervent Ctr, San Francisco, CA 94143 USA

[2] Univ Calif San Francisco, San Francisco Gen Hosp, Epidemiol & Prevent Intervent Ctr, Div Infect Dis, San Francisco, CA 94143 USA

[3] Univ Calif San Francisco, San Francisco Gen Hosp, Epidemiol & Prevent Intervent Ctr, Posit Hlth Program, San Francisco, CA 94143 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2006年 / 43卷 / 07期

关键词：

D O I：

10.1086/507526

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

For antiretroviral therapy, the 95% adherence "threshold" is based on nucloside- exposed patients who are receiving partially suppressive, unboosted protease inhibitor regimens. Using unannounced pill counts and electronic medication monitoring, viral suppression is common with a 54% - 100% mean adherence level to nonnucleoside reverse-transcriptase-inhibitor regimens. Although perfect adherence is an important goal, viral suppression is possible with moderate adherence to potent regimens.

引用

页码：939 / 941

页数：3

共 18 条

[1] Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring
Arnsten, JH
Demas, PA
Farzadegan, H
Grant, RW
Gourevitch, MN
Chang, CJ
Buono, D
Eckholdt, H
Howard, AA
Schoenbaum, EE
[J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (08) : 1417 - 1423
[2] Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness
Bangsberg, DR
Acosta, EP
Gupta, R
Guzman, D
Riley, ED
Harrigan, PR
Parkin, N
Deeks, SG
[J]. AIDS, 2006, 20 (02) : 223 - 231
[3] High levels of adherence do not prevent accumulation of HIV drug resistance mutations
Bangsberg, DR
Charlebois, ED
Grant, RM
Holodniy, M
Deeks, SG
Perry, S
Conroy, KN
Clark, R
Guzman, D
Zolopa, A
Moss, A
[J]. AIDS, 2003, 17 (13) : 1925 - 1932
[4] Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
Bangsberg, DR
Hecht, FM
Charlebois, ED
Zolopa, AR
Holodniy, M
Sheiner, L
Bamberger, JD
Chesney, MA
Moss, A
[J]. AIDS, 2000, 14 (04) : 357 - 366
[5] Is average adherence to HIV antiretroviral therapy enough?
Bangsberg, DR
Deeks, SG
[J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2002, 17 (10) : 812 - 813
[6] Non-adherence to highly active antiretroviral therapy predicts progression to AIDS
Bangsberg, DR
Perry, S
Charlebois, ED
Clark, RA
Roberston, M
Zolopa, AR
Moss, A
[J]. AIDS, 2001, 15 (09) : 1181 - 1183
[7] de Olalla PG, 2002, J ACQ IMMUN DEF SYND, V30, P105, DOI 10.1097/00042560-200205010-00014
[8] Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy
Harrigan, PR
Hogg, RS
Dong, WWY
Yip, B
Wynhoven, B
Woodward, J
Brumme, CJ
Brumme, ZL
Mo, T
Alexander, CS
Montaner, JSG
[J]. JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (03) : 339 - 347
[9] Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up
Hogg, RS
Heath, K
Bangsberg, D
Yip, B
Press, N
O'Shaughnessy, MV
Montaner, JSG
[J]. AIDS, 2002, 16 (07) : 1051 - 1058
[10] Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors
Maggiolo, F
Ravasio, L
Ripamonti, D
Gregis, G
Quinzan, G
Arici, C
Airoldi, M
Suter, F
[J]. CLINICAL INFECTIOUS DISEASES, 2005, 40 (01) : 158 - 163

← 1 2 →